Dataset Information

Modulation factors calculated with an EPID-derived MLC fluence model to streamline IMRT/VMAT second checks.

ABSTRACT: This work outlines the development of a robust method of calculating modulation factors used for the independent verification of MUs for IMRT and VMAT treatments, to replace onerous ion chamber measurements. Two-dimensional fluence maps were calculated for dynamic MLC fields that include MLC interleaf leakage, transmission, and tongue-and-groove effects, as characterized from EPID-acquired images. Monte Carlo-generated dose kernels were then used to calculate doses for a modulated field and that field with the modulation removed at a depth specific to the calculation point in the patient using in-house written software, Mod_Calc. The ratio of these two doses was taken to calculate modulation factors. Comparison between Mod_Calc calculation and ion chamber measurement of modulation factors for 121 IMRT fields yielded excellent agreement, where the mean difference between the two was -0.3% ± 1.2%. This validated use of Mod_Calc clinically. Analysis of 5,271 dynamic fields from clinical use of Mod_Calc gave a mean difference of 0.3% ± 1.0% between Mod_Calc and Eclipse-generated factors. In addition, 99.3% and 96.5% fields pass 5% and 2% criteria, respectively, for agreement between these two predictions. The development and use of Mod_Calc at our clinic has considerably streamlined our QA process for IMRT and RapidArc fields, compared to our previous method based on ion chamber measurements. As a result, it has made it feasible to maintain our established and trusted current in-house method of MU verification, without resorting to commercial software alternatives.

SUBMITTER: Steciw S

PROVIDER: S-EPMC5714641 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Modulation factors calculated with an EPID-derived MLC fluence model to streamline IMRT/VMAT second checks.

Steciw Stephen S Rathee Satyapal S Warkentin Brad B

Journal of applied clinical medical physics 20131108 6

This work outlines the development of a robust method of calculating modulation factors used for the independent verification of MUs for IMRT and VMAT treatments, to replace onerous ion chamber measurements. Two-dimensional fluence maps were calculated for dynamic MLC fields that include MLC interleaf leakage, transmission, and tongue-and-groove effects, as characterized from EPID-acquired images. Monte Carlo-generated dose kernels were then used to calculate doses for a modulated field and that ...[more]

PMID: 24257271

Similar Datasets

Project description:PURPOSE:The goal of this study was to investigate the effectiveness of monitoring relevant variations during treatments for electronic portal imaging device (EPID)-based 3D in vivo verification performed using planning CTs. METHODS:Experiments on two simple phantoms (uniform and nonuniform phantoms) and a thoracic phantom were analyzed in this study, and six relevant variations including the machine output, planning target volume (PTV) deformation, multileaf collimator (MLC) and Phantom shift (set-up errors), and gantry and couch angle shifts were evaluated. 3D gamma and dose-volume histogram (DVH) methods were used to evaluate the detection sensitivity of the EPID-based 3D in vivo dosimetry and the dose accuracy of the EPID reconstruction, respectively, as affected by the variations, and the results were validated by determining the consistency with TPS simulated results. RESULTS:The results of the simple phantoms showed that the gamma failure rates and DVH trend of EPID reconstructions were consistent with the results of TPS simulations for machine output and MLC shifts and inconsistent for phantom shift, gantry/couch angle shift and PTV deformation variations. The results of the thoracic phantom showed that CBCT-guided EPID reconstruction sensitively detected 3-mm Phantom shift in thoracic phantom and its gamma failure rates and DVH trend were consistent with the results of TPS simulations. CONCLUSION:The variations, such as machine output and MLC shift, that are phantom unrelated and cause changes in the beam of the linear accelerator can be sensitively detected by EPID-based 3D in vivo dosimetry and do not affect the accuracy of the EPID reconstruction dose. Planning CT will limit the detection sensitivity and the accuracy of the reconstruction dose of the EPID-based 3D in vivo dosimetry for phantom-related variations (such as Phantom shift and gantry/couch angle shift). EPID reconstruction combined with IGRT technology is a more effective method to monitor phantom shift variations.

Project description:We proposed to perform a basic dosimetry commissioning on a new imager sys-tem, the Varian aS1200 electronic portal imaging device (EPID) and TrueBeam 2.0 linear accelerator for flattened (FF) and flattening filter-free (FFF) beams, then to develop an image-based quality assurance (QA) model for verification of the system delivery accuracy for intensity-modulated radiation therapy (IMRT) treat-ments. For dosimetry testing, linearity of dose response with MU, imager lag, and effectiveness of backscatter shielding were investigated. Then, an image-based model was developed to convert images to planar dose onto a virtual water phantom. The model parameters were identified using energy fluence of the Acuros treatment planning system (TPS) and, reference dose profiles and output factors measured at depths of 5, 10, 15, and 20 cm in water phantom for square fields. To validate the model, its calculated dose was compared to measured dose from MapCHECK 2 diode arrays for 36 IMRT fields at 10 cm depth delivered with 6X, 6XFFF, 10X, and 10XFFF energies. An in-house gamma function was used to compare planar doses pixel-by-pixel. Finally, the method was applied to the same IMRT fields to verify their pretreatment delivery dose compared with Eclipse TPS dose. For the EPID commissioning, dose linearity was within 0.4% above 5 MU and ~ 1% above 2 MU, measured lag was smaller than the previous EPIDs, and profile symmetry was improved. The model was validated with mean gamma pass rates (standard deviation) of 99.0% (0.4%), 99.5% (0.6%), 99.3% (0.4%), and 98.0% (0.8%) at 3%/3 mm for respectively 6X, 6XFFF, 10X, and 10XFFF beams. Using the same comparison criteria, the beam deliveries were verified with mean pass rates of 100% (0.0%), 99.6% (0.3%), 99.9% (0.1%), and 98.7% (1.4%). Improvements were observed in dosimetric response of the aS1200 imager compared to previous EPID models, and the model was successfully developed for the new system and delivery energies of 6 and 10 MV, FF, and FFF modes.

Project description:Commercially available intensity-modulated radiation therapy (IMRT) inverse treatment planning systems (ITPS) typically include a smoothing function which allows the user to vary the complexity of delivered beam fluence patterns. This study evaluated the behavior of three ITPSs when varying smoothing parameters. We evaluated four cases treated with IMRT in our clinic: sinonasal carcinoma (SNC), glioblastoma multiforme (GBM), base of tongue carcinoma (BOT), and prostate carcinoma (PST). Varian Eclipse v6.5, BrainLAB BrainScan v5.31, and Nomos Corvus v6.2 ITPSs were studied for the SNC, GBM, and PST sites. Only Eclipse and Corvus were studied for BOT due to field size constraints of the BrainLAB MM3 collimator. For each ITPS, plans were first optimized using vendor- recommended default "smoothing" values. Treatment plans were then reoptimized, exploring various smoothing values. Key metrics recorded included a delivery complexity (DC) metric and the Ian Paddick Conformality Index (IPCI). Results varied widely by vendor with regard to the impact of smoothing on complexity and conformality. Plans run on the Corvus ITPS showed the logically anticipated increase in DC as smoothing was decreased, along with associated improved organ-at-risk (OAR) sparing. Both Eclipse and BrainScan experienced an expected trend for increased DC as smoothing was decreased. However, this increase did not typically result in appreciably improved OAR sparing. For Eclipse and Corvus, and to a much lesser extent BrainScan, increases in smoothing decreased DC but eventually caused unacceptable losses in plan quality. Depending on the ITPS, potential benefits from optimizing fluence smoothing levels can be significant, allowing for increases in either efficiency or conformality. Because of variability in smoothing function behavior by ITPS, it is important that users familiarize themselves with the effects of varying smoothing parameters for their respective ITPS. Based on experience gained here, we provide recommended workflows for each ITPS to best exploit the fluence-smoothing features of the system.

Project description:PurposeIntensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), two advanced modes of high-precision radiotherapy (RT), have become standard of care in the treatment of head and neck cancer. The development in RT techniques has markedly increased the complexity of target volume definition and accurate treatment delivery. The aim of this study was to indirectly investigate the quality of current TV delineation and RT delivery by analyzing the patterns of treatment failure for head and neck cancer patients in our high-volume RT center.MethodsBetween 2004 and 2014, 385 patients with pharyngeal, laryngeal, and oral cavity tumors were curatively treated with primary RT (IMRT/VMAT). We retrospectively investigated locoregional recurrences (LRR), distant metastases (DM), and overall survival (OS).ResultsMedian follow-up was 6.4 years (IQR 4.7-8.3 years) during which time 122 patients (31.7%) developed LRR (22.1%) and DM (17.7%). The estimated 2- and 5-year locoregional control was 78.2% (95% CI 73.3, 82.3) and 74.2% (95% CI 69.0, 78.8). One patient developed a local recurrence outside the high-dose volume and five patients developed a regional recurrence outside the high-dose volume. Four patients (1.0%) suffered a recurrence in the electively irradiated neck and two patients had a recurrence outside the electively irradiated neck. No marginal failures were observed. The estimated 2- and 5-year DM-free survival rates were 83.3% (95% CI 78.9, 86.9) and 80.0% (95% CI 75.2, 84.0). The estimated 2- and 5-year OS rates were 73.6% (95% CI 68.9, 77.8) and 52. 6% (95% CI 47.3, 57.6). Median OS was 5.5 years (95% CI 4.5, 6.7).ConclusionTarget volume definition and treatment delivery were performed accurately, as only few recurrences occurred outside the high-dose regions and no marginal failures were observed. Research on dose intensification and identification of high-risk subvolumes might decrease the risk of locoregional relapses. The results of this study may serve as reference data for comparison with future studies, such as dose escalation or proton therapy trials.

Project description:A first-time survey across 15 cancer centers in Ontario, Canada, on the current practice of patient-specific quality assurance (PSQA) for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) delivery was conducted. The objectives were to assess the current state of PSQA practice, identify areas for potential improvement, and facilitate the continued improvement in standardization, consistency, efficacy, and efficiency of PSQA regionally. The survey asked 40 questions related to PSQA practice for IMRT/VMAT delivery. The questions addressed PSQA policy and procedure, delivery log evaluation, instrumentation, measurement setup and methodology, data analysis and interpretation, documentation, process, failure modes, and feedback. The focus of this survey was on PSQA activities related to routine IMRT/VMAT treatments on conventional linacs, including stereotactic body radiation therapy but excluding stereotactic radiosurgery. The participating centers were instructed to submit answers that reflected the collective view or opinion of their department and represented the most typical process practiced. The results of the survey provided a snapshot of the current state of PSQA practice in Ontario and demonstrated considerable variations in the practice. A large majority (80%) of centers performed PSQA measurements on all VMAT plans. Most employed pseudo-3D array detectors with a true composite (TC) geometry. No standard approach was found for stopping or reducing frequency of measurements. The sole use of delivery log evaluation was not widely implemented, though most centers expressed interest in adopting this technology. All used the Gamma evaluation method for analyzing PSQA measurements; however, no universal approach was reported on how Gamma evaluation and pass determination criteria were determined. All or some PSQA results were reviewed regularly in two-thirds of the centers. Planning related issues were considered the most frequent source for PSQA failures (40%), whereas the most frequent course of action for a failed PSQA was to review the result and decide whether to proceed to treatment.

Dataset Information

Modulation factors calculated with an EPID-derived MLC fluence model to streamline IMRT/VMAT second checks.

Publications

Modulation factors calculated with an EPID-derived MLC fluence model to streamline IMRT/VMAT second checks.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets